Progress: Procedure completed
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | ENVI | SOMMER Renate ( PPE), GENTILE Elena ( S&D), PIECHA Bolesław G. ( ECR), MEISSNER Gesine ( ALDE), AFFRONTE Marco ( Verts/ALE), D'ORNANO Mireille ( EFDD) |
Lead committee dossier:
Legal Basis:
RoP 136-p5
Legal Basis:
RoP 136-p5Subjects
Events
The European Parliament adopted a resolution tabled by the Committee on the Environment, Public Health and Food Safety on vaccine hesitancy and the drop in vaccination rates in Europe.
Parliament noted that vaccination prevents an estimated 2.5 million deaths each year worldwide and reduces disease-specific treatment costs, including antimicrobial treatments. Accordingly, it noted with concern that epidemiological data on the current vaccination situation in Member States show important gaps in the acceptance of vaccines and that the vaccination coverage rates necessary to ensure adequate protection are insufficient. Members were concerned that growing and widespread vaccine hesitancy has assumed worrying proportions. In this connection, it pointed out that Europe is currently facing avoidable measles outbreaks in a number of countries owing to vaccine hesitancy.
The resolution called on Member States and the Commission to reinforce the legal basis for immunisation coverage . It pointed out that, according to objective 1 of the European Vaccine Action Plan 2015–2020, introducing an appropriate legislative framework is crucial to defining national priorities.
Increasing coverage : Parliament called on the Commission to:
facilitate a more harmonised and better aligned schedule for vaccination across the EU, to share best practices, to explore, together with Member States, options for establishing an EU platform for the monitoring of the safety and effectiveness of vaccines, to ensure even coverage across Europe, to reduce health inequalities and to help boost trust in vaccines; establish targeted vaccination initiatives , such as a ‘European influenza vaccination day’, which could be used each year to launch the vaccination campaign in line with the 75 % coverage target laid down in the Council recommendations on seasonal influenza.
It welcomed the forthcoming launch of a Joint Action co-funded by the EU’s Health Programme aimed at increasing vaccination coverage.
Testing and assessment: Members pointed out that vaccines are rigorously tested through multiple stages of trials before being prequalified by the WHO and approved by the European Medicines Agency (EMA), and regularly reassessed. Recalling that researchers must declare any conflicts of interest, Parliament proposed that researchers subject to a conflict of interest be excluded from evaluation panels. In addition:
the confidentiality of the deliberations of the EMA’s evaluation panel should be lifted; the scientific and clinical data which inform the conclusions of the panel, and whose anonymity is guaranteed in advance, should be made public.
Transparency : noting the importance of transparency in building and maintaining public trust in medicines, Parliament called for greater transparency in:
the production of vaccines and for measures to reassure European citizens; the process of evaluating vaccines and their adjuvants, and the funding of independent research programmes on their possible side- effects.
Public awareness : Members emphasised the need to provide citizens with inclusive, factual and science-based information. They called for dialogue with stakeholders from civil society, grassroots movements, academia, the media and national health authorities in order to combat unreliable, misleading and unscientific information on vaccination.
Procurement of vaccines : Parliament was concerned at the limited budget allocated specifically to vaccination in some Member States, as well as the high prices and wide variations in price of some life-saving vaccines. It strongly supported the Joint Procurement Agreement, which gives Member States and the Commission a framework to jointly procure vaccines, thereby pooling the purchasing power of Member States.
Members noted that the cost of a full vaccines package for one child, even at the lowest global prices, increased by a factor of 68 between 2001 and 2014. This price increase was held to be unjustifiable and incompatible with the Sustainable Development Goal of ensuring healthy lives and promoting wellbeing at all ages.
Documents
- Commission response to text adopted in plenary: SP(2018)401
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament: T8-0188/2018
- Motion for a resolution: B8-0188/2018
- Motion for a resolution: B8-0195/2018
- Debate in Parliament: Debate in Parliament
- Oral question/interpellation by Parliament: B8-0011/2018
- Oral question/interpellation by Parliament: B8-0012/2018
- Amendments tabled in committee: PE616.893
- Amendments tabled in committee: PE616.893
- Oral question/interpellation by Parliament: B8-0011/2018
- Oral question/interpellation by Parliament: B8-0012/2018
- Motion for a resolution: B8-0188/2018
- Motion for a resolution: B8-0195/2018
- Commission response to text adopted in plenary: SP(2018)401
Activities
- Marco AFFRONTE
Plenary Speeches (1)Institutional Motions (1)Oral Questions (2)
- Elena GENTILE
Plenary Speeches (1)Institutional Motions (1)Oral Questions (2)
- Gesine MEISSNER
Plenary Speeches (1)Institutional Motions (1)Oral Questions (2)
- Bolesław G. PIECHA
Plenary Speeches (1)Institutional Motions (1)Oral Questions (2)
- Renate SOMMER
Plenary Speeches (1)Institutional Motions (1)Oral Questions (2)
- Mireille D'ORNANO
Institutional Motions (1)Oral Questions (2)
- Jonathan ARNOTT
Plenary Speeches (1)
- Ivo BELET
Plenary Speeches (1)
- Arne GERICKE
Plenary Speeches (1)
- María Teresa GIMÉNEZ BARBAT
Plenary Speeches (1)
- Urszula KRUPA
Plenary Speeches (1)
- Notis MARIAS
Plenary Speeches (1)
- Stefano MAULLU
Plenary Speeches (1)
- Momchil NEKOV
Plenary Speeches (1)
- Claudiu Ciprian TĂNĂSESCU
Plenary Speeches (1)
- Tadeusz ZWIEFKA
Plenary Speeches (1)
Votes
B8-0188/2018 - § 11 19/04/2018 12:39:37.000 #
IT | ES | SE | BE | PT | DE | LT | NL | RO | CZ | EE | DK | EL | CY | BG | AT | IE | LU | MT | FI | HR | SI | FR | LV | GB | HU | SK | PL | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total |
59
|
37
|
16
|
18
|
19
|
73
|
10
|
22
|
28
|
17
|
5
|
8
|
5
|
1
|
12
|
18
|
10
|
3
|
5
|
8
|
10
|
6
|
61
|
7
|
55
|
13
|
9
|
41
|
|
S&D |
149
|
Italy S&DFor (27)Alessia Maria MOSCA, Andrea COZZOLINO, Brando BENIFEI, Cécile Kashetu KYENGE, Damiano ZOFFOLI, Daniele VIOTTI, David Maria SASSOLI, Elena GENTILE, Elly SCHLEIN, Enrico GASBARRA, Flavio ZANONATO, Goffredo Maria BETTINI, Isabella DE MONTE, Luigi MORGANO, Massimo PAOLUCCI, Mercedes BRESSO, Michela GIUFFRIDA, Nicola CAPUTO, Nicola DANTI, Patrizia TOIA, Pier Antonio PANZERI, Pina PICIERNO, Renata BRIANO, Renato SORU, Roberto GUALTIERI, Silvia COSTA, Simona BONAFÈ
|
Sweden S&D |
4
|
Portugal S&DFor (7) |
Germany S&DFor (20)Arndt KOHN, Arne LIETZ, Bernd LANGE, Constanze KREHL, Evelyne GEBHARDT, Gabriele PREUSS, Ismail ERTUG, Jakob von WEIZSÄCKER, Jo LEINEN, Maria NOICHL, Martina WERNER, Michael DETJEN, Norbert NEUSER, Peter SIMON, Petra KAMMEREVERT, Susanne MELIOR, Sylvia-Yvonne KAUFMANN, Tiemo WÖLKEN, Udo BULLMANN, Ulrike RODUST
|
2
|
2
|
4
|
2
|
1
|
1
|
1
|
Austria S&D |
1
|
2
|
1
|
2
|
1
|
United Kingdom S&DFor (18) |
2
|
2
|
2
|
||||||
ALDE |
56
|
2
|
Belgium ALDEFor (6) |
1
|
2
|
3
|
Netherlands ALDEFor (7) |
2
|
4
|
3
|
2
|
4
|
1
|
1
|
1
|
2
|
1
|
1
|
France ALDEFor (6) |
1
|
1
|
||||||||
Verts/ALE |
45
|
1
|
Spain Verts/ALE |
4
|
2
|
Germany Verts/ALEFor (10) |
1
|
2
|
1
|
1
|
3
|
1
|
1
|
France Verts/ALEFor (5)Against (1) |
1
|
United Kingdom Verts/ALEFor (5) |
1
|
||||||||||||
GUE/NGL |
35
|
3
|
Spain GUE/NGLFor (6) |
1
|
4
|
Germany GUE/NGLFor (7) |
3
|
1
|
2
|
4
|
1
|
2
|
1
|
||||||||||||||||
EFDD |
35
|
Italy EFDDFor (11)Abstain (1) |
2
|
1
|
1
|
1
|
3
|
United Kingdom EFDDAgainst (13)Abstain (1) |
1
|
||||||||||||||||||||
NI |
8
|
1
|
1
|
1
|
3
|
2
|
|||||||||||||||||||||||
ENF |
30
|
Italy ENFFor (1)Against (4) |
1
|
1
|
2
|
4
|
France ENFAgainst (15) |
2
|
|||||||||||||||||||||
ECR |
51
|
1
|
2
|
Germany ECRAgainst (5) |
1
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
United Kingdom ECRAgainst (14) |
1
|
16
|
||||||||||||||
PPE |
167
|
Italy PPEFor (1)Against (9) |
1
|
3
|
Portugal PPEFor (1)Against (6) |
Germany PPEAgainst (27)
Albert DESS,
Andreas SCHWAB,
Angelika NIEBLER,
Axel VOSS,
Birgit COLLIN-LANGEN,
Burkhard BALZ,
Christian EHLER,
Daniel CASPARY,
Dennis RADTKE,
Dieter-Lebrecht KOCH,
Elmar BROK,
Hermann WINKLER,
Ingeborg GRÄSSLE,
Jens GIESEKE,
Joachim ZELLER,
Manfred WEBER,
Michael GAHLER,
Monika HOHLMEIER,
Norbert LINS,
Peter JAHR,
Peter LIESE,
Rainer WIELAND,
Renate SOMMER,
Sabine VERHEYEN,
Sven SCHULZE,
Thomas MANN,
Werner LANGEN
|
2
|
Netherlands PPE |
Romania PPEFor (1)Against (10) |
Czechia PPEAgainst (6) |
1
|
1
|
Bulgaria PPEFor (1)Against (5) |
5
|
4
|
2
|
3
|
3
|
5
|
4
|
France PPEFor (1)Against (15) |
4
|
1
|
Hungary PPEFor (1)Against (6) |
Slovakia PPEAgainst (6) |
Poland PPEAgainst (18)
Adam SZEJNFELD,
Agnieszka KOZŁOWSKA,
Andrzej GRZYB,
Barbara KUDRYCKA,
Bogdan Andrzej ZDROJEWSKI,
Bogdan Brunon WENTA,
Czesław Adam SIEKIERSKI,
Danuta JAZŁOWIECKA,
Danuta Maria HÜBNER,
Dariusz ROSATI,
Janusz LEWANDOWSKI,
Jarosław KALINOWSKI,
Jarosław WAŁĘSA,
Jerzy BUZEK,
Julia PITERA,
Krzysztof HETMAN,
Marek PLURA,
Tadeusz ZWIEFKA
|
Amendments | Dossier |
101 |
2017/2951(RSP)
2018/01/31
ENVI
101 amendments...
Amendment 1 #
Citation 1 a (new) - having regard to Article 6 of the Treaty on the Functioning of the European Union,
Amendment 10 #
Recital F a (new) F a. Whereas, in the period of 2008- 2015, there were 215,000 cases of Vaccine Preventable Diseases (VPDs), excluding influenza, in Europe1a. _________________ 1aCouncil on Foreign Relations (2015), "Vaccine-Preventable Outbreak Maps" 2015.
Amendment 100 #
Paragraph 20 20. Calls on the Member States to punctually provide data on vaccination to the European Centre for Disease Prevention and Control;
Amendment 101 #
Paragraph 20 20. Calls on the Member States to punctually provide data on vaccination coverage to the Commission and the WHO;
Amendment 11 #
Recital F a (new) Fa. having regard also to the increasing numbers of intercontinental travellers;
Amendment 12 #
Paragraph 1 a (new) 1 a. Recognises the potential role vaccines can play in reducing the need for antibiotics, thereby helping to limit the spread of Anti-Microbial Resistance (AMR), which should continue to be explored; stresses however that urgently reducing the overuse and misuse of, and unintended exposure to, antibiotics must remain a top priority.
Amendment 13 #
Paragraph 1 a (new) 1 a. Notes that vaccination prevents an estimated 2.5 million deaths each year worldwide and reduces disease-specific treatment costs, including antimicrobial treatments;
Amendment 14 #
Paragraph 2 2. Welcomes that the introduction of the large-scale protective vaccinations in Europe has significantly contributed to the eradication or decline in many infectious diseases;
Amendment 15 #
Paragraph 2 2. Welcomes that the introduction of the large-scale protective vaccinations in Europe has significantly contributed to the eradication or decline in many infectious diseases;
Amendment 16 #
Paragraph 2 2. Welcomes that the introduction of the large-scale protective vaccinations in Europe has significantly contributed to the eradication or decline in many infectious diseases;
Amendment 17 #
Paragraph 3 3. Points out that
Amendment 18 #
Paragraph 3 3. Points out that
Amendment 19 #
Paragraph 3 3. Points out that
Amendment 2 #
Citation 15 a (new) - having regard to Council Recommendation on seasonal influenza vaccination (2009);
Amendment 20 #
Paragraph 3 3. Points out that Vaccines are safe according to the WHO and the European Medicines Agency (EMA), as a licensed vaccine is rigorously tested across multiple phases of trials before its use is approved, and regularly reassessed once it is on the market;
Amendment 21 #
Paragraph 3 3. Points out that
Amendment 22 #
Paragraph 3 a (new) 3a. Points out that the content of individual leaflets is questionable when it comes to the adverse effects that might occur as a result of vaccination; points out that, in this situation, there is a legitimate need for independent testing to be carried out with the aim of checking discrepancies that have been reported; points out that patients must have full, detailed and accurate information on the vaccines that are available on the market, so that they can choose the right one for their child;
Amendment 23 #
Paragraph 3 a (new) 3a. Proposes that researchers subject to a conflict of interest be excluded from evaluation panels; calls for the confidentiality of the deliberations of the evaluation panel of the European Medicines Agency (EMEA) to be lifted; proposes that the scientific and clinical data which informs the conclusions of the panel, and whose anonymity is guaranteed in advance, be made public;
Amendment 24 #
Paragraph 3 a (new) 3a. Recalls that the European One Health Action Plan against Antimicrobial Resistance (AMR) observes that immunisation through vaccination is a cost-effective public health intervention in efforts to combat antimicrobial resistance1a; _________________ 1a European Commission (29, June 2017), A European One Health Action Plan against Antimicrobial Resistance (AMR), p. 10.
Amendment 25 #
Paragraph 4 4. Welcomes the active engagement of the Commission on the issue of vaccination and the inclusion of a
Amendment 26 #
Paragraph 4 4. Welcomes the active engagement of the Commission on the issue of vaccination and the i
Amendment 27 #
Paragraph 4 4.
Amendment 28 #
Paragraph 4 a (new) 4 a. Calls on the Commission to elaborate guidelines defining conditions (coverage percentage, epidemic phenomena, etc.) and criteria that can conduct to a compulsory vaccination mechanism, in order to have harmonized guidelines for all Member States.
Amendment 29 #
Paragraph 4 a (new) 4a. Expresses its support for the fact that in its AMR Action Plan the Commission announces that it will provide incentives to increase the uptake of diagnostics, antimicrobial alternatives and vaccines1a; _________________ 1a European Commission (29, June 2017), A European One Health Action Plan against Antimicrobial Resistance (AMR), p. 12.
Amendment 3 #
Recital B B. whereas cost of a full vaccines package for one child, even at the lowest global prices, has increased by a factor of 68 from 2001 to 2014; whereas this price increase is unjustifiable and incompatible with the Sustainable Development Goal to ensure healthy lives and promote well- being at all ages;
Amendment 30 #
Paragraph 4 a (new) 4 a. Welcomes the forthcoming launch of a Joint Action co-funded by the EU Health Programme aimed at increasing vaccination coverage;
Amendment 31 #
Paragraph 4 b (new) 4 b. Calls on the Member States and the Commission to reinforce legislative basis for immunization coverage. According to the objective 1 of the European Vaccine Action Plan 2015– 2020, introducing and implementing an appropriate legislative framework is crucial to define national priorities and to concretize a sustainable commitment to immunization.
Amendment 32 #
Paragraph 4 c (new) 4 c. Stresses the importance to create an innovative financing mechanism to allocate funding for immunisation at affordable prices and high-quality supply, identifying any funding gaps thorough MS, in line with the goal 6 and the objective 5 of the European Vaccine Action Plan 2015–2020, in order to achieve financial sustainability of national immunization programmes.
Amendment 33 #
Paragraph 5 5. Strongly supports the Joint Procurement Agreement, which gives Member States and the Commission a framework to jointly procure vaccines, thereby pooling the purchasing power of Member States, ensuring that pandemic vaccines are available in sufficient quantities and avoiding any risk of stocks running out, that access to vaccines is guaranteed, and that all participating Member States are treated equally;
Amendment 34 #
Paragraph 5 5. Strongly supports the Joint Procurement Agreement, which gives Member States and the Commission a framework to jointly procure vaccines, thereby pooling the purchasing power of Member States, ensuring that pandemic vaccines and other vaccines are available in sufficient quantities that access to vaccines is guaranteed, and that all participating Member States are treated equally;
Amendment 35 #
Paragraph 6 6. Welcomes the fact that 24 Member States have signed the Joint Procurement Agreement, meaning that the Agreement covers 447.8 million of the 508.2 million EU citizens; calls on those Member States which have not yet signed the Joint Procurement Agreement to do so to ensure that all EU citizens are covered by the agreement; calls on the Commission to look into the possibility of extending the pooling of purchasing power to all Member States of the European Economic Area and of the Council of Europe;
Amendment 36 #
Paragraph 7 7. Recalls the importance of transparency in building and maintaining public trust in medicines; recommends in that vein the importance a) of commissioning independent trials and studies of all vaccinations, and b) publication of the results of those trials and studies;
Amendment 37 #
Paragraph 7 7. Recalls the importance of transparency in building and maintaining public trust in medicines, including vaccines, given the growing phenomenon of vaccine hesitancy in several Member States;
Amendment 38 #
Paragraph 7 a (new) 7 a. Whereas in order to ensure the highest protection of human health and to reduce vaccine hesitancy, the chances of any negative health effects resulting from, or perceived to result from vaccinations, however rare, need to be reduced as much as possible; Calls on Member States to consider the introduction of a preventive and precautionary pre-vaccination test, at least for some fragile and vulnerable categories of patients, which takes into consideration, inter alia, their age, intolerances and health condition, in order to help prevent any adverse health reactions and to therefore also counter vaccine hesitancy.
Amendment 39 #
Paragraph 8 8. Recalls the importance of the Clinical Trials Regulation in stimulating and facilitating research into new vaccinations and ensuring transparency of results of clinical trials; calls on the Commission and the European Medicines Agency to implement the Clinical Trials Regulation without further delay and to promote publication of the results, in order to inform the public in the Member States and provide reassurance with respect to any concerns they may have;
Amendment 4 #
Recital C C.
Amendment 40 #
Paragraph 8 8. Recalls the importance of the Clinical Trials Regulation in stimulating and facilitating research into new vaccinations and ensuring transparency of results of clinical trials; calls on the Commission and the European Medicines Agency to implement the Clinical Trials Regulation without further delay; in particular through setting up the European Portal and Database (EUPD) whose implementation has seen significant delays of over two years;
Amendment 41 #
Paragraph 8 – subparagraph 1 (new) Further calls upon all parties involved to ensure that the current process of relocating the EMA away from London does not cause any additional disruption or delays to the work of the Agency;
Amendment 42 #
Paragraph 9 9. Calls on Member States to ensure that all healthcare workers are sufficiently vaccinated themselves; calls on the Commission to address the vaccination rates of healthcare workers in the
Amendment 43 #
Paragraph 9 9. Calls on Member States to ensure that all healthcare workers are sufficiently vaccinated themselves; calls on the Commission to
Amendment 44 #
Paragraph 9 a (new) 9 a. Believes that the initiative of the European Commission regarding the Strengthened cooperation against vaccine preventable diseases, due to be presented the second quarter of 2018 in the form of Council Recommendations on supporting Member States in implementing vaccination programmes, reducing vaccine hesitancy strengthening the supply of vaccines and overall improving vaccination coverage, is a good step; Calls the European Commission and the Council to take into account the position of the European Parliament in the drafting of the recommendations;
Amendment 45 #
Paragraph 10 10. Notes with concern that epidemiological data on the current situation of vaccination in the Member States shows important gaps in the uptake of vaccines and insufficient vaccination coverage rates necessary to ensure adequate protection; is concerned that widespread vaccine hesitancy has become a worrying phenomenon due to the range of health-related consequences it causes in the Member States; is alarmed at the spread of false information on the internet, which is contributing to public hesitancy;
Amendment 46 #
Paragraph 10 10. Notes with concern that epidemiological data on the current situation of vaccination in the Member States shows important gaps in the
Amendment 47 #
Paragraph 10 – subparagraph 1 (new) Calls on the Member States, given the usefulness of vaccination as a preventive tool, to ensure that vaccine coverage is extended beyond early childhood and that all population groups can be included in a lifelong vaccination approach;
Amendment 48 #
Paragraph 10 a (new) 10 a. Underlines that the waning of public confidence in vaccination worldwide is a cause for concern and a major challenge for public health experts; notes that Europe is currently facing avoidable measles outbreaks in a number of countries owing to vaccine hesitancy; calls on the Commission to keep reinforcing its support to national vaccination efforts to increase coverage;
Amendment 49 #
Paragraph 10 a (new) 10a. Stresses that increased transparency in the process of evaluating vaccines and their adjuvants and the funding of independent research programmes on their possible side-effects would contribute to restoring confidence in vaccination;
Amendment 5 #
Recital D a (new) Da. whereas, in accordance with Article 6 of the Treaty on the Functioning of the European Union, the protection and improvement of human health are supporting competences, in respect of which the Commission is authorised to act only to support, coordinate or supplement the actions of the Member States, and whereas, therefore, legally binding acts of the European Union cannot require harmonisation of the laws and regulations of the European States,
Amendment 50 #
Paragraph 10 a (new) 10 a. Calls on the Commission and Members States to strengthen the infrastructure for data collection to track infectious disease patterns and the real-life impact of vaccines to support the delivery of immunisation programmes.
Amendment 51 #
Paragraph 11 Amendment 52 #
Paragraph 11 11. Is concerned by the wide variation in the vaccines that are recommended, provided and/or mandated by different Member States and by the insufficient financial support for vaccination provided by the social security authorities in a number of Member States; is concerned that this variation in vaccination coverage exacerbates health inequalities between Member States and undermines efforts to reduce and eliminate preventable diseases;
Amendment 53 #
Paragraph 12 12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to take effective steps
Amendment 54 #
Paragraph 12 12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to take effective steps
Amendment 55 #
Paragraph 12 12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to
Amendment 56 #
Paragraph 12 12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; points out that vaccination hesitancy has also been fuelled by media sensationalism and by poor journalism that gives "false balance" in which, for example, anecdotal stories are presented as the counter balance for strong scientific evidence; calls on Member States and the Commission to take effective steps against the spread of such misinformation and to further develop awareness and information campaigns, especially for parents, including the creation of a European platform aimed at increasing vaccination coverage;
Amendment 57 #
Paragraph 12 12. Condemns the spread of unreliable, misleading and unscientific information on vaccination aggravated by media controversies; calls on Member States and the Commission to take effective steps against the spread of such misinformation and to further develop awareness and information campaigns, especially for parents, including the creation of a European platform aimed at increasing vaccination coverage, while nevertheless upholding freedom of expression, as education must take precedence over censorship, the perverse effect of which is to consolidate unfounded beliefs;
Amendment 58 #
Paragraph 12 a (new) 12 a. Emphasises the need for inclusive, factual and science-based information to citizens; calls on the Commission and Member States to facilitate dialogue with stakeholders from civil society, grass root movements, academia, media and national health authorities in order to combat unreliable, misleading and unscientific information on vaccination;
Amendment 59 #
Paragraph 12 a (new) 12 a. Notes that future EU incentives on vaccination could tackle vaccine hesitancy in the context of the growing impact of digitalisation and social media, using vaccines as the case study for combating fake news in the EU;
Amendment 6 #
Recital E a (new) E a. Whereas, according to a global survey undertaken by the Vaccine Confidence Project, the European region has the highest negative responses in terms of perception of the importance of vaccines and their safety and effectiveness, leading to the highest degree of vaccine hesitancy in the population1a. _________________ 1aLarson, Heidi J. et al. (2016). The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016; Volume 12, 295 – 301.
Amendment 60 #
Paragraph 13 13. Is concerned about the
Amendment 61 #
Paragraph 13 13. Is concerned about the high prices of
Amendment 62 #
Paragraph 13 13. Is concerned about the high prices and large differences in price of some life- saving vaccines within and outside the EU; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines; further calls on the Commission to improve transparency in the cost of research, development and production of vaccines;
Amendment 63 #
Paragraph 13 13. Is concerned about the alarmingly high prices of some life-saving vaccines
Amendment 64 #
Paragraph 13 13. Is concerned about the high prices of some life-saving vaccines and that this risks further exacerbating existing health inequalities in society; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines;
Amendment 65 #
Paragraph 13 13. Is concerned about the high prices
Amendment 66 #
Paragraph 13 13. Is concerned about the high prices of some life-saving vaccines; calls on the Commission and the Member States to implement the measures called for in the European Parliament’s report of 14 February 2017 on EU options for improving access to medicines and include them in the upcoming Council Recommendations;
Amendment 67 #
Paragraph 14 14. Is concerned that high vaccine prices disproportionately affect low and middle income countries, including countries that are losing donor support through Gavi, the Vaccine Alliance; calls on the Commission and Member States to take measures to help facilitate access to vaccines in those countries; calls, therefore, on social security institutions to step up their demands in negotiations with pharmaceutical companies on the setting of vaccine prices;
Amendment 68 #
Paragraph 14 14. Is concerned that high vaccine prices disproportionately affect low and middle income countries, including countries that are losing donor support through Gavi, the Vaccine Alliance; calls on the Commission and Member States to take measures to help facilitate cheap access to vaccines in those countries;
Amendment 69 #
Paragraph 14 a (new) 14 a. Calls on the Commission to ensure that any development of new vaccines which receives public funding through the EU delivers more affordable end products by applying access conditions such as price ceilings or equitable licensing conditions;
Amendment 7 #
Recital E a (new) Ea. whereas mass vaccination can eradicate a number of diseases and thus avoid epidemics which could cause many deaths;
Amendment 70 #
Paragraph 15 Amendment 71 #
Paragraph 15 15.
Amendment 72 #
Paragraph 15 15. Welcomes the encouraging progress made in the fight against
Amendment 73 #
Paragraph 15 a (new) 15 a. Deplores the persisting inequalities between women and men in participation in clinical trials, which may hinder medicinal research and the development of vaccines for diseases where a majority of patients are women; calls on the Commission and Member States to take measures to eliminate this discriminating gender gap;
Amendment 74 #
Paragraph 16 16. Believes providing vaccination services for migrants and refugees entering EU countries is critical since mass vaccination can eradicate a number of diseases and thus avoid epidemics which could cause many deaths; calls on the Commission and Member States to map what concrete vaccination activities are being implemented for migrants and refugees entering EU countries and work to address the identified gaps;
Amendment 75 #
Paragraph 16 16. Believes providing vaccination screening and vaccination services for migrants and refugees entering EU countries is critical; calls on the Commission and Member States to map what concrete vaccination activities are being implemented for migrants and refugees entering EU countries and work energetically to address the identified gaps;
Amendment 76 #
Paragraph 16 16. Believes providing vaccination services for migrants and refugees
Amendment 77 #
Paragraph 16 a (new) 16 a. Is concerned by vaccine shortages and calls on the Commission and the Member States to develop solutions to increase vaccine supply and availability, including arrangements for stockpiling vaccines;
Amendment 78 #
Paragraph 17 17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians, nurses and pharmacists who provide vaccinations underlining their obligation
Amendment 79 #
Paragraph 17 17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among
Amendment 8 #
Recital F a (new) Fa. whereas, on the basis of the 'One Health' approach, various Member States regard vaccination of agricultural and domestic animals as an important measure both to prevent outbreaks of cross-border animal diseases and to limit the risk of further contagion, and have introduced it, including against infections by Coxiella burnettii and other bacterial and viral diseases which also present public health risks;
Amendment 80 #
Paragraph 17 17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians who provide vaccinations underlining their obligations, including providing patients (or patients’ legal guardians) with sufficient information about compulsory and recommended vaccines so that they can make an informed decision;
Amendment 81 #
Paragraph 17 17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians who provide vaccinations underlining their obligations, including providing patients (or patients’ legal guardians) with sufficient information about recommended vaccines so that they can make an informed decision; calls for disciplinary accountability to be introduced for doctors who fail to provide such information;
Amendment 82 #
Paragraph 17 17. Calls on the Member States and on the Commission to promote awareness- raising campaigns among physicians who provide vaccinations, underlining their obligations, including providing patients (or patients’ legal guardians) with sufficient information about recommended vaccines so that they can make an informed decision;
Amendment 83 #
Paragraph 17 a (new) 17a. Points out that doctors often fail to provide all the information on the benefits of vaccines and on adverse effects that might occur after administration of one vaccine or another; points out that in this situation there is a need for doctors also to inform parents about possible adverse effects, and for sanctions to be imposed where doctors fail to comply with that obligation;
Amendment 84 #
Paragraph 17 a (new) 17 a. Points out that health-care professionals are the cornerstone of public acceptance of vaccination and their recommendations are consistently cited as a primary reason for vaccination1a. _________________ 1aLeask J, Kinnersley P, Jackson C, Cheater F, Bedford H, Rowles G. Communicating with parents about vaccination: a framework for health professionals. BMC Pediatr 2012;12:154.
Amendment 85 #
Paragraph 18 18. Calls on the Commission and the Member States to elaborate a fully comprehensive EU Action Plan raising the social problem of vaccine hesitancy, strengthening Member States’ commitments, including priority and region-specific actions,
Amendment 86 #
Paragraph 18 18. Calls on the
Amendment 87 #
Paragraph 18 18. Calls on the Commission and the Member States to elaborate a fully comprehensive EU Action Plan raising the social problem of vaccine hesitancy, strengthening Member States’ commitments to immunization as a priority public health measure, including priority and region-specific actions, and taking into account the varying circumstances and specific challenges faced by the Member States;
Amendment 88 #
Paragraph 19 19. Calls on the Commission to facilitate a more harmonised and better aligned schedule for vaccination across the EU, to share best practice, ensure even coverage across Europe
Amendment 89 #
Paragraph 19 19. Calls on the Commission to
Amendment 9 #
Recital F a (new) Fa. whereas in some Member States public mistrust of vaccines is growing significantly, leading to a worrying refusal to vaccinate;
Amendment 90 #
Paragraph 19 19. Calls on the Commission to facilitate a more harmonised schedule for vaccination across the EU, to share best practice, to explore with Member States options to establish an EU platform for the monitoring of the safety and effectiveness of vaccines, to ensure even coverage across Europe and reduce health inequalities;
Amendment 91 #
Paragraph 19 19. Calls on the Commission to facilitate a more harmonised schedule for vaccination across the EU, to share best practice, ensure even coverage across Europe and reduce costs and health inequalities;
Amendment 92 #
Paragraph 19 – subparagraph 1 (new) Calls on the Commission to establish targeted vaccination initiatives, such as a 'European influenza vaccination day’, which could be used each year to launch the vaccination campaign in line with the 75% coverage target laid down in the Council recommendations on seasonal influenza;
Amendment 93 #
Paragraph 19 a (new) 19a. Calls on the Member States to introduce voluntary vaccination, ensuring that all those who are prepared to be vaccinated have access to free vaccines, and, in countries in which vaccination is compulsory, to set up funds to compensate those who experience adverse effects following vaccination; points out that in countries like Poland, where vaccination is compulsory, and additionally the subject of coercion on the part of the state, there is no compensation fund for those who experience adverse effects following vaccination; proposes that funds be introduced in all Member States to compensate those who experience adverse effects following vaccination;
Amendment 94 #
Paragraph 19 a (new) 19a. Calls on the Commission and Member States to adopt concrete 'One Health' measures to increase vaccination rates in both humans and, where necessary, animals by means of financial and policy incentives, and thus to combat infectious diseases and also antibiotic resistance more cost-effectively, inter alia in the context of the future Common Agricultural Policy beyond 2020;
Amendment 95 #
Paragraph 19 b (new) 19b. Calls on the Member States to set up a targeted compensation fund to provide financial support and rehabilitation for people who have experienced complications following vaccination; points out that forced vaccination is a breach of the Convention for the Protection of Human Rights and Fundamental Freedoms; points out that the European Court of Human Rights, for example, has taken such a position with regard to compulsory vaccination, stating that coercion is a breach of Article 8 of the Convention for the Protection of Human Rights and Fundamental Freedoms: ‘The Commission recalls that private life [...] includes a person’s physical and psychological integrity’ (No 32647/96, Decision of 1.7.1998, DR 94, p. 91-93); points out that the Court examined an application on the basis of Article 8 of the Convention, which stipulates: ‘1. Everyone has the right to respect for his private and family life, his home and his correspondence. 2. There shall be no interference by a public authority with the exercise of this right except such as is in accordance with the law and is necessary in a democratic society in the interests of national security, public safety or the economic well-being of the country, for the prevention of disorder or crime, for the protection of health or morals, or for the protection of the rights and freedoms of others’; points out that the Court considers that compulsory vaccination, as compulsory medical intervention, constitutes interference with the right to respect for private life guaranteed by Article 8(1);
Amendment 96 #
Paragraph 19 c (new) 19c. Calls on the Member States to monitor the adverse effects caused by vaccines, to keep registers of the adverse effects of vaccinations, to bring in judicial oversight of those records, and to take action to minimise or eliminate adverse effects caused by vaccines;
Amendment 97 #
Paragraph 19 d (new) 19d. Points out that although a register of the adverse effects of vaccinations is kept in Poland, it does not always reflect the actual situation; points out that the body whose job it is to keep the register has conflicting responsibilities, in that it is also responsible for ensuring that vaccination rates remain sufficiently high; points out that this justifies the need for registers of adverse effects to be monitored by independent courts that are not involved in ruling on the cases concerned;
Amendment 98 #
Paragraph 20 20. Calls on the Member States to punctually provide data on vaccination; Moreover, member States have to monitor and report every year to the regional offices all progresses made, remaining challenges and updated actions to reach the national immunizations targets.
Amendment 99 #
Paragraph 20 20. Calls on the Member States to punctually provide data on vaccination and the situation with regard to the spread and reduction of diseases which can be prevented by means of vaccines;
source: 616.893
|
History
(these mark the time of scraping, not the official date of the change)
events/0/docs |
|
committees/0/rapporteur/4 |
|
docs/0/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE616.893New
https://www.europarl.europa.eu/doceo/document/ENVI-AM-616893_EN.html |
docs/3/docs/0/url |
Old
http://www.europarl.europa.eu/doceo/document/B-8-2018-0188_EN.htmlNew
https://www.europarl.europa.eu/doceo/document/B-8-2018-0188_EN.html |
docs/4/docs/0/url |
Old
http://www.europarl.europa.eu/doceo/document/B-8-2018-0195_EN.htmlNew
https://www.europarl.europa.eu/doceo/document/B-8-2018-0195_EN.html |
events/0/docs |
|
events/2 |
|
events/2 |
|
docs/3/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B8-2018-0188&language=ENNew
http://www.europarl.europa.eu/doceo/document/B-8-2018-0188_EN.html |
docs/4/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B8-2018-0195&language=ENNew
http://www.europarl.europa.eu/doceo/document/B-8-2018-0195_EN.html |
docs/5/body |
EC
|
events/2/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2018-0188New
http://www.europarl.europa.eu/doceo/document/TA-8-2018-0188_EN.html |
committees/0 |
|
committees/0 |
|
activities |
|
commission |
|
committees/0 |
|
committees/0 |
|
docs |
|
events |
|
links |
|
other |
|
procedure/dossier_of_the_committee |
Old
ENVI/8/11391New
|
procedure/legal_basis/0 |
Rules of Procedure EP 136-p5
|
procedure/legal_basis/0 |
Rules of Procedure EP 128-p5
|
procedure/subject |
Old
New
|
activities/0/docs |
|
activities/0/type |
Old
Debate in plenary scheduledNew
Debate in Parliament |
activities/1/docs |
|
activities/1/type |
Old
Vote in plenary scheduledNew
Results of vote in Parliament |
procedure/stage_reached |
Old
Awaiting Parliament 1st reading / single reading / budget 1st stageNew
Procedure completed |
procedure/title |
Old
Vaccine hesitancy and drop in vaccination rates in EuropeNew
Resolution on vaccine hesitancy and the drop in vaccination rates in Europe |
activities/0/type |
Old
Indicative plenary sitting date, 1st reading/single readingNew
Debate in plenary scheduled |
activities/1 |
|
activities |
|
committees |
|
links |
|
other |
|
procedure |
|